Ribocure Pharmaceuticals AB, together with its parent company Suzhou Ribo Life Science Co., Ltd (Ribolia) Life Science Co., Ltd., has submitted a Phase 2b Clinical Trial Application (CTA) in Europe for vortosiran (RBD4059), a novel siRNA therapy targeting Factor XI (FXI) for the prevention of thromboembolic events in patients with atrial fibrillation.
LINK Medical is supporting the program as Contract Research Organization (CRO), responsible for clinical trial management and operational execution. As part of this role, LINK Medical contributes with expertise in site identification and feasibility, preparation of clinical documentation, and CTA submission activities—supporting timely study start-up and planned initiation of patient recruitment.
We congratulate the Ribocure team on this important submission and look forward to continued collaboration as the trial progresses.
Read more on: Ribo Submits Phase 2b Clinical Trial Application for world’s first siRNA FXI inhibitor in atrial fibrillation – Ribocure Pharmaceuticals
